SELL ACC Limited — Nomura India Research
byNomura India ResearchHorizon: NA (inferred 1 year)30 Oct 2026via ET Now (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.
Long-term trend bearish — 200-day average falling over the past quarter
Technicals · trend·30 Oct · today
Adani-group owned ACC’s consolidated profit slumps 92% on year in September quarter
NewsEt-Markets·27 Oct · 2d ago
5 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · same horizon·29 Oct · yesterday
Ambuja Cements ACC Merger NCLT Hearing Date Set
NewsGoogle News·13 Oct · 2w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on ACC
- BUY — Choice Broking29 Oct 2026 · ~1 year · target ₹1,445 · Active
- BUY — Nirav Chheda, Nirmal Bang Securities19 Oct 2026 · ~2 weeks · target ₹1,220 · SL hit
- BUY — VLA Ambala19 Oct 2026 · ~2 weeks · target ₹1,500 · Active
- BUY — Choice Broking4 Sept 2026 · ~1 year · target ₹1,700 · Active
- BUY — Vinay Rajani, HDFC Securities4 Aug 2026 · ~2 weeks · target ₹1,460 · SL hit
More from Nomura India Research
- BUY Restaurant Brands Asia30 Oct 2026 · ~1 year · target ₹106 · Active
- BUY Trent30 Oct 2026 · ~1 year · target ₹3,410 · Active
- BUY Medplus Health Services30 Oct 2026 · ~1 year · target ₹915 · Active
- BUY United Spirits30 Oct 2026 · ~1 year · target ₹1,600 · Active
- BUY Sun Pharmaceutical Industries30 Oct 2026 · ~1 year · target ₹2,400 · Active

